Retinal detachment with macular hole following intravitreal bevacizumab in patient with severe proliferative diabetic retinopathy

2008 ◽  
Vol 92 (5) ◽  
pp. 717-718 ◽  
Author(s):  
Y. Mitamura ◽  
K. Ogata ◽  
T. Oshitari ◽  
N. Asaumi ◽  
S. Yamamoto
2021 ◽  
Author(s):  
MEI-CHI TSUI ◽  
Yi-Ting Hsieh ◽  
Tso-Ting Lai ◽  
Chun-Ting Lai ◽  
Hsuan-Chieh Lin ◽  
...  

Abstract BackgroundTo investigate the formation pathways of full-thickness macular hole (FTMH) in proliferative diabetic retinopathy (PDR) with fibrovascular proliferation (FVP).MethodsTwenty-one consecutive patients (21 eyes) having PDR and FVP with optical coherence tomography (OCT) available before and after FTMH formation were retrospectively reviewed. Fundus abnormalities and OCT features were studied.ResultsFour different types of FTMH formation pathways in PDR were observed. Type 1 was characterized by epiretinal membrane (ERM) and/or vitreomacular traction (VMT) inducing foveoschisis, intraretinal cysts or foveal detachment, followed by formation of a FTMH or macular hole retinal detachment (MHRD). In type 2, ERM and/or FVP induced lamellar macular hole (LMH) with foveoschisis, followed by the formation of FTMH or MHRD. Type 3 was characterized by the initial tractional retinal detachment (TRD) with foveal cysts and/or foveoschisis and the subsequent formation of MHRD. Type 4 was characterized by TRD associated with foveal thinning, ensued by the formation of MHRD. Severity and locations of FVP varied with different types. Eyes with MHRD had poorer best-corrected visual acuity, higher proportion of active FVP, and higher rate of TRD.ConclusionFour types of FTMH formation pathways in PDR were identified and were quite different from those in idiopathic conditions. Spontaneous closure of FTMHs in PDR might be observed. The activity, severity and locations of FVP varied in PDR eyes destined to develop FTMHs.


Author(s):  
Filemon Darabe ◽  
William Makupa

Introduction: Diabetic retinopathy is one of the rigorous microvascular complications of diabetes mellitus is the significant cause of visual impairment and consequently blindness affecting about 36% of the diabetic population. Diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) are two prime manifestations of DR that are responsible for visual morbidity. The basis of the treatment in PDR is Laser photocoagulation as accomplished by Diabetic retinopathy treatment study (DRS) and early treatment diabetic retinopathy study (ETDRS) for the last two decades. The dawn of intravitreal anti-VEGF agents has revolutionized the management of diabetic eye disease for more than the last decade. The aim of the study is to compare the visual outcomes of diabetic retinopathy patients between pan-retinal photocoagulation and pan-retinal photocoagulation plus intravitreal Bevacizumab. Methodology: A hospital-based cross-section study using medical record information for all DR patients treated by PRP and IVB at the KCMC eye. Data were analyzed using SPSS version 20. Results: A number of 204 patients were included in the study. The mean age was 59.26 (SD=9.6) years; 75.4% were male. Most of the patients 71.1% are from Arusha and Kilimanjaro. Among all, 51% had PRP alone and the duration of Diabetes was 5-10 years in the majority. The mean VA for PRP alone was 0.89 (SD=0.89) before treatment while it was 1 (SD=0.99) in PRP plus Bevacizumab. At 3 months after treatment VA for PRP alone was 0.947 (SD=0.93) and 0.96 (SD=1.01) for PRP plus Bevacizumab. The mean difference was not statistically significant. VA improved by 49% and it deteriorated by 27.7%. The majority had early proliferated DR 49.7%, 42.8% high risk proliferated DR and advanced proliferated DR was 7.5%. The complications were found in 5.6% and they included: vitreous hemorrhage (4.6%) and retinal detachment (1%) in PRP plus Bevacizumab and none in PRP alone. Conclusion: With respect to this study there is no significant difference in visual outcome for PRP alone and PRP plus injection Bevacizumab, though PRP plus Bevacizumab in treatment of DR had better visual outcome over PRP alone. PRP plus injection Bevacizumab is associated with a higher and early rate of regression of active NVs than PRP alone in patients with PDR. Further studies will be needed to determine whether IVB plus PRP is a satisfactory treatment for the prevention of vision-threatening complications such as vitreous hemorrhage and tractional retinal detachment.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Mei-Chi Tsui ◽  
Yi-Ting Hsieh ◽  
Tso-Ting Lai ◽  
Chun-Ting Lai ◽  
Hsuan-Chieh Lin ◽  
...  

AbstractTwenty-one consecutive patients (21 eyes) having proliferative diabetic retinopathy (PDR) and fibrovascular proliferation (FVP) with optical coherence tomography (OCT) available before and after full-thickness macular hole (FTMH) formation were retrospectively reviewed. Four types of FTMH formation pathways in PDR were identified and were quite different from those in idiopathic conditions. The activity, severity and locations of FVP varied in PDR eyes destined to develop FTMHs. Type 1 was characterized by epiretinal membrane (ERM) and/or vitreomacular traction (VMT) inducing foveoschisis, intraretinal cysts or foveal detachment, followed by formation of a FTMH or macular hole retinal detachment (MHRD). In type 2, ERM and/or FVP induced lamellar macular hole (LMH) with foveoschisis, followed by the formation of FTMH or MHRD. Type 3 was characterized by the initial tractional retinal detachment (TRD) with foveal cysts and/or foveoschisis and the subsequent formation of MHRD. Type 4 was characterized by TRD associated with foveal thinning, ensued by the formation of MHRD. The severity of FVP was grade 2 in 66.7% of eyes in both types 1 and 4, and grade 3 in 75% of eyes in type 3 while the severity of FVP was more evenly distributed in type 2.


Sign in / Sign up

Export Citation Format

Share Document